Drew Fromkin takes the helm at Langer's Blend Therapeutics

Drew Fromkin

Blend Therapeutics, which was founded by Omid Farokhzad and MIT's Robert Langer, has named Drew Fromkin as its new CEO. Fromkin's first task will be to oversee the filing of an IND for Blend's lead drug, BTP-114, later this quarter with another IND planned for next year. Blend's using technology that the Harvard and MIT founders helped develop, creating miniaturized drug conjugates that use a targeting ligand tied to a cell killer and incorporated in nanoparticles designed to cluster in tumors. Fromkin was CEO of Clinical Data, which Forest bought out in 2011 for $1.2 billion. Release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.